---
schema_version: "secwatch.filing_event.v1"
accession: "0001639691-24-000139"
form_type: "8-K"
ticker: "LIVN"
cik: "0001639691"
company_name: "LivaNova PLC"
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:57:37.258309+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact

## Summary
- CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.
- LivaNova says it is disappointed by the decision but does not expect any impact on its business.
- The company plans to continue pursuing improved reimbursement for VNS Therapy for DRE.

## SEC filing metadata
- accession: 0001639691-24-000139
- form_type: 8-K
- ticker: LIVN
- cik: 0001639691
- company_name: LivaNova PLC
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000139/0001639691-24-000139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1639691/000163969124000139/livn-20241101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001639691-24-000139
- JSON: https://secwatch.observer/filing/0001639691-24-000139.json
- Plain text: https://secwatch.observer/filing/0001639691-24-000139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.